Sanofi (SNY)
(Delayed Data from NSDQ)
$56.33 USD
+0.22 (0.39%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $56.32 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.33 USD
+0.22 (0.39%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $56.32 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
Zacks News
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
by Zacks Equity Research
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
by Kinjel Shah
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens
Alphabet's Healthcare Push Gains Steam: Others Brace Up
by Shilpa Mete
Alphabet's (GOOGL) Google's partnership with Sanofi provides it a competitive edge in the healthcare sector.
Sanofi Partners Google to Build Healthcare Innovation Lab
by Zacks Equity Research
Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
Protalix (PLX) Completes Enrollment in Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
by Zacks Equity Research
Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
by Zacks Equity Research
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Sanofi (SNY) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
by Kinjel Shah
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Novartis Appoints New Pharma Unit Head, Gives Other Updates
by Zacks Equity Research
Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
by Kinjel Shah
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
by Zacks Equity Research
GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product
by Zacks Equity Research
Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Amarin Rises on Priority Review for Vascepa Label Expansion
by Zacks Equity Research
Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
BioMarin Announces Data on Hemophilia Candidate, Shares Fall
by Zacks Equity Research
BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.
Alphabet to Aid Pharma Giants Enhance Clinical Trial Process
by Zacks Equity Research
Alphabet's (GOOGL) Verily joins hands with Novartis, Sanofi, Otsuka and Pfizer to revolutionize the clinical trial methods.
Lilly (LLY) Launches Half-Priced Version of Humalog Insulin
by Zacks Equity Research
Eli Lilly (LLY) offers a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
Pfizer's Eczema Candidate Meets All Goals in Phase III Study
by Zacks Equity Research
Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
Regeneron (REGN) Stock Down on Earnings, Sales Miss in Q1
by Zacks Equity Research
Regeneron's (REGN) first-quarter performance was dismal with the company missing on both earnings and sales estimates.
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
Emergent (EBS) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.